

Adenovirus vector core facility

An adenovirus vector core facility, financed by the Swedish National Gene Therapy Program, has been established at the Biomedical Center (BMC) in Uppsala. The facility will help investigators throughout Sweden to construct and produce state-of-the-art recombinant adenovirus vectors for use in gene transfer experiments. The facility has the proper expertise, equipment and permissions to work with viral vectors of low risk (L-verksamhet, AFS 2000:5). The facility does not operate under GMP-standards, and therefore cannot produce viral stocks for use in human clinical trials. The facility will also provide practical education on the reconstruction, handling, growth and purification of recombinant adenoviruses to interested research groups.

Core Facility Operation

- Adenovirus vectors based on the AdEasy system (<http://www.qbiogene.com/products/adenovirus/adeasy.html>) will be produced on a routine basis. Recombinant viruses based on alternative vector strategies can also be considered. Please inquire.
- Investigators are expected to clone the gene of interest into a suitable shuttle plasmid. Several variants of such shuttle vectors are available from the facility.
- The staff at the facility will reconstruct, isolate and purify a recombinant virus based on the supplied shuttle plasmid. The final virus will be verified by restriction endonuclease cleavage. However, DNA sequencing of inserts, or functional test for the inserted gene will not be done at the facility.
- The customer will receive a small-scale virus preparation (approximately 2 ml, $>10^9$ PFU/ml).
- Estimated time for virus construction, 8-10 weeks.
- Recombinant viruses will be constructed and produced free of charge for the Swedish academic community. At a later stage a small charge covering the cost of reagents and material will be asked for.

Please contact Josef Seibt (josef.seibt@imbim.uu.se) for additional information.